Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
'Patients are Waiting'over 1 year ago
Patient Treatment & Travel: The Need for Stepped-Up Supportover 1 year ago
A Biosimilars Roadmap: Understanding Payer Perceptionsover 1 year ago
Avoiding the Digital Age is Hurting Research Effortsover 1 year ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 1 year ago
Yvonne Greenstreet: Answering the CallNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
President Trump Announces Nine More TrumpRx Participants
5

